Gemcitabine and carboplatin for pretreated metastatic breast cancer: The predictive value of immunohistochemically defined subtypes

International Journal of Clinical Oncology

Volumn 18, Issue 2, 2013, Pages 343-349

  Nelli, Fabrizio ^a   Moscetti, Luca ^a   Natoli, Guido ^a   Massari, Annalisa ^a   D'Auria, Giuliana ^a   Chilelli, Mario ^a   Fabbri, Maria Agnese ^a   Frittelli, Patrizia ^a   Ruggeri, Enzo Maria ^a  

^a BELCOLLE HOSPITAL   (Italy)

Author keywords

Breast cancer; Carboplatin; Gemcitabine; Metastatic; Predictive value; Subtypes

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; CARBOPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GEMCITABINE; KI 67 ANTIGEN; LAPATINIB; NAVELBINE; PROGESTERONE RECEPTOR; TAXANE DERIVATIVE; TRASTUZUMAB;

ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; BREAST CANCER; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER HORMONE THERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL ARTICLE; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; DRUG RESPONSE; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; HER 2 NEGATIVE BREAST CANCER; HER 2 POSITIVE BREAST CANCER; HUMAN; HUMAN TISSUE; HYPERTRANSAMINASEMIA; IMMUNOHISTOCHEMISTRY; LEUKOPENIA; LUMINAL A BREAST CANCER; LUMINAL B BREAST CANCER; METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PREDICTIVE VALUE; PRIORITY JOURNAL; SIDE EFFECT; SURVIVAL TIME; THROMBOCYTOPENIA; TIME TO PROGRESSION; TRIPLE NEGATIVE BREAST CANCER;

AGED; BREAST NEOPLASMS; CARBOPLATIN; DEOXYCYTIDINE; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM METASTASIS; PREDICTIVE VALUE OF TESTS; RECEPTOR, ERBB-2; SURVIVAL ANALYSIS;

EID: 84880923023     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-012-0384-x     Document Type: Article

References (30)

1. Jemal A, Siegel R, Ward E et al (2009) Cancer statistics. CA Cancer J Clin 59:225-249
2. Bernard-Marty C, Cardoso F, Piccart MJ (2004) Facts and controversies in systemic treatment of metastatic breast cancer. Oncologist 9:617-632
3. Hamilton A, Hortobagyi G (2005) Chemotherapy: what progress in the last 5 years? J Clin Oncol 23:1760-1775
4. Carrick S, Parker S, Thornton CE et al (2009) Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev 15:CD003372
5. Mauri D, Polyzos NP, Salanti G et al (2008) Multiple-treatments meta-analysis of chemotherapy and targeted therapies in advanced breast cancer. J Natl Cancer Inst 17:1780-1791
6. Moreno-Aspitia A, Perez EA (2009) Treatment options for breast cancer resistant to anthracycline and taxane. Mayo Clin Proc 84:533-545
7. Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN (2007) Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol 608:1-22
8. Perez EA (2004) Gemcitabine and platinum combinations in patients with breast cancer previously treated with anthracyclines and/or taxanes. Clin Breast Cancer 4(Suppl 3):S113-S116
9. Nasr FL, Chahine GY, Kattan JG et al (2004) Gemcitabine plus carboplatin combination therapy as second-line treatment in patients with relapsed breast cancer. Clin Breast Cancer 5:117-122
10. Loesch D, Asmar L, McIntyre K et al (2008) Phase II trial of gemcitabine/carboplatin (plus trastuzumab in HER2-positive disease) in patients with metastatic breast cancer. Clin Breast Cancer 8:178-186
11. Laessig D, Stemmler HJ, Vehling-Kaiser U et al (2007) Gemcitabine and carboplatin in intensively pretreated patients with metastatic breast cancer. Oncology 73:407-414
12. Brandi M, Vici P, Lopez M et al (2004) Novel association with gemcitabine and docetaxel as salvage chemotherapy in metastatic breast cancer previously treated with anthracyclines: results of a multicenter phase II study. Semin Oncol 31:13-19
13. Cheang MC, Chia SK, Voduc D et al (2009) Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 101:736-750
14. Wolff AC, Hammond ME, Schwartz JN et al (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 131:18-43
15. Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10
16. Onitilo AA, Engel JM, Greenlee RT et al (2009) Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clin Med Res 7:4-13
17. Wiechmann L, Sampson M, Stempel M et al (2009) Presenting features of breast cancer differ by molecular subtype. Ann Surg Oncol 16:2705-2710
18. Goldhirsch A, Wood WC, Coates AS et al (2011) Strategies for subtypes - dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 22:1736-1747
19. Jones RL, Salter J, A'Hern R et al (2009) Relationship between oestrogen receptor status and proliferation in predicting response and long-term outcome to neoadjuvant chemotherapy for breast cancer. Breast Cancer Res Treat 119:315-323
20. Jones RL, Salter J, A'Hern R et al (2009) The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat 16:53-68
21. Hugh J, Hanson J, Cheang MC et al (2009) Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol 27:1168-1176
22. Perou CM, Sørlie T, Eisen MB et al (2000) Molecular portraits of human breast tumours. Nature 406:747-752
23. Sørlie T, Perou CM, Tibshirani R et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98:10869-10874
24. Rouzier R, Perou CM, Symmans WF et al (2005) Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11:5678-5685
25. Pusztai L (2008) Current status of prognostic profiling in breast cancer. Oncologist 13:350-360
26. de Ronde JJ, Hannemann J, Halfwerk H et al (2009) Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response. Breast Cancer Res Treat 119:119-126
27. Desmedt C, Haibe-Kains B, Wirapati P et al (2008) Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res 14:5158-5165
28. Elliott RL, Blobe GC (2005) Role of transforming growth factor beta in human cancer. J Clin Oncol 23:2078-2093
29. Thuerigen O, Schneeweiss A, Toedt G et al (2006) Gene expression signature predicting pathologic complete response with gemcitabine, epirubicin, and docetaxel in primary breast cancer. J Clin Oncol 24:1839-1845
30. Bai J, Sata N, Nagai H (2007) Gene expression analysis for predicting gemcitabine sensitivity in pancreatic cancer patients. HPB (Oxford) 9:150-155